Business Context and Reporting Period
This Form 8-K was filed by Nile Therapeutics, Inc. on July 9, 2013, reporting events occurring on July 7, 2013. The filing announces the entry into a definitive merger agreement with Capricor, Inc., a privately held biotechnology company focused on cardiac stem cell therapeutics.
Key Financial Metrics
This filing is a current report regarding a material definitive agreement and does not contain standard financial statements (revenue, profit, cash flow, or margins) for either entity. The only specific financial figure disclosed is a condition for closing: the satisfaction of accrued liabilities and obligations of Nile Therapeutics not to exceed $72,000 as of the effective time of the Merger.
Material Changes and Transaction Structure
- Merger Agreement: Nile Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger with Capricor, Inc. and Bovet Merger Corp. (a wholly-owned subsidiary of the Company).
- Transaction Outcome: Upon completion, Capricor will become a wholly-owned subsidiary of Nile Therapeutics.
- Ownership Structure: Post-merger, holders of Capricor capital stock will collectively own 90% of the total number of shares of the Company's common stock on a fully-diluted basis.
- Consideration: Outstanding Capricor common stock and convertible securities will convert into the right to receive shares of the Company's common stock or convertible securities.
Conditions, Risks, and Outlook
The closing of the Merger is subject to several material conditions and risks:
- Stockholder Approvals: Requires approval by the requisite number of Capricor stockholders and Nile Therapeutics stockholders.
- Reverse Stock Split: Nile Therapeutics must amend its Certificate of Incorporation to authorize a reverse split of its common stock at a ratio not to exceed 1-for-100.
- Debt and Liabilities: The Company must amend its technology license agreement with the Mayo Foundation and provide evidence of payment or satisfaction of accrued liabilities not exceeding $72,000.
- Preferred Stock Conversion: All shares of Company preferred stock must convert into Company common stock.
- Termination Date: The agreement may be terminated if the closing does not occur prior to September 30, 2013.
- Securities Registration: Securities issued in the Merger are not registered under the Securities Act and cannot be offered or sold in the U.S. absent registration or an applicable exemption.
Investor Verification Checklist
- Verify the status of the 1-for-100 reverse stock split approval by Nile Therapeutics stockholders.
- Confirm the resolution of the Mayo Foundation technology license agreement amendment.
- Monitor the September 30, 2013 deadline for the closing of the transaction.
- Review the full text of the Merger Agreement (Exhibit 2.1) for specific representations and warranties not detailed in this summary.
- Check for any updates regarding the $72,000 liability cap and its satisfaction.